Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Tevogen Bio Holdings, Inc. (TVGN)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$5.56-2.80%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for TVGN yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Improve EPS losses from -10 to less negative levels | Recent EPS estimates show a slight improvement from -11 to -10 in 2026. | Improving | EPS loss worsens beyond -10 in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 13, 2026
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making business rather than an established compounder. The thesis is in a watch state: operating losses have narrowed, but the evidence is limited and confidence is low.
The evidence snapshot does not include valuation measures or a clear account of market expectations, so whether the shares look cheap or expensive versus peers is unclear. The main visible expectations gap is operational: progress toward managing losses is limited, and profitability milestones for a potential special dividend remain unmet.
Over the multi-year view, narrower operating losses suggest some improvement, but quarterly net losses and negative operating cash flow show that the business has not established profitability. Near term, earnings miss risk is elevated because recent surprises have been erratic, while healthcare sector momentum has strengthened. TVGN regained Nasdaq listing compliance by 2026-Q3, but loss management remains a stated priority.
The multi-year thesis depends on whether TVGN can keep reducing operating losses and improve cash flow enough to reach its financial milestones. Near term, a weakening jobs report could increase recession concerns for cyclical names, while continued strong results from healthcare bellwethers such as VRTX, REGN, and MRNA could support the sector backdrop. Misses or lower guidance from those companies could weaken that tailwind.
For the next 1 to 3 years, TVGN remains a high-risk, watch-state thesis: loss trends have improved, but persistent losses, uncertain valuation evidence, and elevated near-term earnings risk limit confidence. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Tevogen aims to resolve Nasdaq listing issues and meet financial milestones for a special dividend. |
| Improving |
| No progress or deterioration in financial milestones over next 4 quarters |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Resolve Nasdaq listing compliance issues | Tevogen aims to resolve Nasdaq listing issues and meet financial milestones for a special dividend. | Recovered | Nasdaq issues remain unresolved beyond next 4 quarters | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-13.01 → $-13.01 · observed estimates
$0.50B → $0.50B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-07-25 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-07-26 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-07-27 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-07-28 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-07-29 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-07-30 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-07-31 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-08-01 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-08-02 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-08-03 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-08-04 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-08-05 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-08-06 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-08-08 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-08-09 | $-13.00 | $0 | 1 / 1 |
| 2026-08-10 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-08-12 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-08-13 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-08-14 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-08-15 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-08-16 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-08-17 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-08-18 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-08-19 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-08-20 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-08-21 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-08-22 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-08-23 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-08-24 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-08-25 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-08-26 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-08-27 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-08-28 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-08-29 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-08-30 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-08-31 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-09-01 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-09-02 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-09-03 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-09-04 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-09-05 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-09-06 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-09-07 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-09-08 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-09-09 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-09-10 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-09-11 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-09-12 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-09-13 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-09-14 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-09-15 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-09-16 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-09-17 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-09-18 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-09-19 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-09-20 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-09-21 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-09-22 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-09-23 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-09-24 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-09-25 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-09-26 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-09-27 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-09-28 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-09-29 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-09-30 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-10-01 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-10-02 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-10-03 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-10-04 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-10-05 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-10-06 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-10-07 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-10-08 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-10-09 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-10-10 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-10-11 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-10-12 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-10-13 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-10-14 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-10-15 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-10-16 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-10-17 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-10-18 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-10-19 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-10-20 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-10-21 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-10-22 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-10-23 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-10-24 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-10-25 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-10-26 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-10-27 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-10-28 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-10-29 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-10-30 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-10-31 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-11-01 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-11-02 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-11-03 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-11-04 | $-13.01 | $502,272,000 | 1 / 1 |
| 2026-11-05 | $-13.01 | $502,272,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 0 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.